Abstract: The application provides fusion proteins comprising an adeno-associated virus (AAV)-binding polypeptide and a polypeptide having phase behavior. Furthermore, the application provides purification matrices comprising these AAV-binding polypeptides, and methods of using the same for purifying AAV particles.

Abstract: Provided herein are fusion proteins and methods of use thereof to purify nucleic acids from a composition. The disclosed compositions and methods allow for faster, more efficient purification of nucleic acids compared to traditional affinity chromatography.

Abstract: Provided herein are fusion proteins comprising a first polypeptide and a second polypeptide, wherein the second polypeptide has phase behavior. The first polypeptide may be a polypeptide having a desirable biological activity, such as a polypeptide with therapeutic, cosmetic, and/or industrial importance. Fusing the first polypeptide to the polypeptide with phase behavior facilitates purification thereof, and may also help to stabilize the first polypeptide during expression, storage, or after exposure to various conditions known to unfold, degrade, or misfold proteins.

Abstract: Disclosed herein are fusion proteins comprising the CR3 domain of the low density lipoprotein (LDLR) and a polypeptide with phase behavior. Also provided herein are polypeptides with phase behavior. Additionally provided herein are methods of improving or decreasing viral transduction efficiency comprising administering a fusion protein or polypeptide with phase behavior described herein.

Abstract: Disclosed herein are AAV binding proteins and methods of making and using the same.

Abstract: Disclosed herein are purification matrices comprising adeno-associated virus (AAV)-binding polypeptides and methods of using the same.

Abstract: Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.

Abstract: Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.

Abstract: Described herein are peptide biopolymers that exhibit controlled phase separation based on their amino acid sequence, aromatic:aliphatic ratio, hydrophobicity, temperature, molecular weight, and concentration.

Abstract: Described herein are protein nanoparticles comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide, in one aspect, the nanoparticles comprise a di-block of repeats of a core polypeptide, repeats of a corona polypeptide, and one or more binding proteins. The nanoparticles can be used as therapeutic agents, targeted-delivery agents, separation agents, or purification agents.

Abstract: Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.

Abstract: Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.